The Relative Strength (RS) Rating for Oric Pharmaceuticals entered a new percentile Thursday, with an increase from 75 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the best-performing stocks tend to have an 80 or better RS Rating in the early stages of their moves.
Oric Pharmaceuticals is building a cup with handle with an 11.27 buy point. See if it can clear the breakout price in heavy volume.
Oric Pharmaceuticals showed 0% EPS growth in its most recent report, while sales growth came in at 0%.
Oric Pharmaceuticals earns the No. 289 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
